Salute e Benessere
Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight
Discover which therapies are expected to grab the major moderate-to-severe acute pain treatment market share @
The total number of incident cases of moderate-to-severe acute pain in the 7MM were around in 2024. These numbers are further expected to increase by 2034.
There is a growing demand for non-opioid therapies that match opioid-level efficacy but with fewer side effects and lower dependency risks, creating a significant opportunity for innovative drug development.
The emerging pipeline for postoperative acute pain treatments is quite robust, featuring numerous mid- and late-stage development products such as Arthritis Innovation/Medincell (F14), Oculis (OCS-01), Neumentum (NTM-001), Tris Pharma (cebranopadol [TRN-228]), Viatris (meloxicam [MR 107A 02]), Xgene Pharmaceutical (XG005), Allay Therapeutics (ATX101), and others, which hold significant potential for improving pain management options.
Emerging drugs with novel mechanisms of action, like NaV1.8 channel inhibitors (e.g., VX-548) and corticosteroids (e.g., SVT-15473), show high potential in acute pain management, offering strong efficacy with fewer side effects.
The management of acute pain, whether postoperative or non-postoperative, typically involves a multimodal strategy that integrates both pharmacological and non-pharmacological treatments. Commonly used medications include (NSAIDs), such as antidepressants, muscle relaxants, and cannabinoids. Non-drug interventions like (TENS) are employed to enhance treatment effectiveness and reduce dependence on a single therapy.
In the moderate-to-severe acute pain market, key therapies for postoperative pain include (suzetrigine) by Vertex Pharmaceuticals, (acetaminophen and ibuprofen) by Hikma Pharmaceuticals, Hyloris Pharmaceuticals, and AFT Pharmaceuticals, (bupivacaine and meloxicam) from Heron Therapeutics, and (loteprednol etabonate ophthalmic gel) from Bausch & Lomb, among others.
represents a promising alternative to opioids in acute pain management, with its novel mechanism and non-addictive profile. While early adoption is encouraging, its commercial success will depend on insurance coverage, pricing strategies, and broader clinical efficacy. The high cost of JOURNAVX could be a barrier because this healthcare system generally prioritizes the least expensive alternative. Even with JOURNAVX's approval, and investigation of several non-opioid pain relief not just in acute pain but in other pain indications, opioids remain essential in pain management when used correctly, particularly when analgesia fails.
In 2025, the US FDA approved three novel therapies for the acute treatment of migraine in moderate-to-severe acute pain cases: (dihydroergotamine mesylate), (meloxicam and rizatriptan), and (dihydroergotamine mesylate) by Amneal Pharmaceuticals. (capsaicin) 8% topical system is expected to report topline data in Q4 2025, with Averitas Pharma planning to file a supplemental new drug application (sNDA) in 2026, pending positive outcomes.
In Japan , acute pain treatment options are relatively scarce, with only a few approved drugs like and , alongside several off-label therapies for moderate-to-severe pain. Some non-opioid options, such as and , were withdrawn due to limited market uptake or safety concerns. The ophthalmic therapy (bromfenac sodium) remains available but is largely genericized. These patterns underscore persistent regulatory, safety, and market access challenges in the acute pain treatment space.
There remains a significant need for safe, effective, non-opioid alternatives for postoperative pain management. Within the moderate-to-severe acute pain segment, non-post-operative acute pain represents the dominant share, driven by its higher number of cases and high-revenue generating therapies compared to post-operative cases.
To know more about moderate-to-severe acute pain treatment guidelines, visit @
The pipeline for postoperative acute pain treatments is strong, with several promising mid- and late-stage candidates that could enhance pain management. Key companies in this space include (F14), (OCS-01), (PRF-110), (CPL-01), (NTM-001), (cebranopadol), (meloxicam), (XG005), (ATX101), (LTG-001), (HT-6184), and others.
is a sustained-release formulation of celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), developed to alleviate pain and inflammation while supporting recovery following total knee replacement (TKR). mdc-CWM is administered directly into the intra-articular space at the conclusion of TKR surgery and is intended to provide pain relief lasting for several weeks postoperatively. The therapy is currently being assessed in a Phase III trial for TKR-related pain management.
is an oral investigational therapy that selectively inhibits Nav1.8, a sodium channel critical in pain signaling. By blocking peripheral sensory neurons that transmit pain signals, LTG-001 prevents their relay to the central nervous system, potentially delivering effective pain relief without the risks linked to opioid use.
is a first-in-class investigational agent that acts as a dual agonist of the Nociceptin/Orphanin FQ Peptide (NOP) and µ-opioid Peptide (MOP) receptors. These receptors share partial homology but play complementary and distinct roles in modulating pain pathways. Cebranopadol is being explored for the treatment of moderate-to-severe pain as well as opioid use disorder.
is a preservative-free, high-concentration dexamethasone eye drop developed with the OPTIREACH technology platform. Designed as the first once-daily steroid option for ocular use, it aims to reduce inflammation and pain following eye surgery.
The anticipated launch of these emerging therapies are poised to transform the moderate-to-severe acute pain market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the moderate-to-severe acute pain market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about moderate-to-severe acute pain marketed and pipeline drugs @
Moderate-to-severe acute pain is a sudden onset of pain that is intense, often arising due to tissue injury, trauma, surgery, or medical conditions such as fractures, burns, infections, or acute inflammatory episodes. It is typically short-lived, lasting from a few hours to days or weeks, but its severity can significantly affect daily functioning and quality of life.
Common moderate-to-severe acute pain symptoms include sharp, stabbing, or throbbing pain localized to the affected area, along with swelling, redness, reduced mobility, and sometimes autonomic signs like sweating or increased heart rate. Diagnosis involves a detailed patient history to understand the onset, nature, and intensity of pain, as well as physical examinations and imaging studies like X-rays, MRIs, or CT scans to identify underlying causes. Laboratory tests may also be performed if infections or inflammatory conditions are suspected. Early recognition and accurate diagnosis are crucial to managing acute pain effectively and preventing its progression to chronic pain.
The moderate-to-severe acute pain epidemiology section provides insights into the historical and current moderate-to-severe acute pain patient pool and forecasted trends for the leading markets. In the 7MM, the US accounted for the highest number of incident cases of acute pain, with nearly cases in 2024. In the US, about of cases observed were of moderate acute pain, and for severe acute pain.
The moderate-to-severe acute pain market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets segmented into:
Download the report to understand which factors are driving moderate-to-severe acute pain market trends @
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute pain companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key postoperative pain companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key postoperative acute pain companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-postoperative acute pain companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/moderate-to-severe-acute-pain-market-anticipates-impressive-growth-trajectory-at-a-cagr-of-14-during-the-study-period-20202034--delveinsight-302565466.html